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Purpose/Objective: Pulmonary emphysema (PE) is a non 
functional lung region due to destruction of the gas-
exchanging tissues. This information is never integrated into 
the radiotherapy (RT) plan for lung cancer (LC). With Myrian© 
software dedicated to radiology, an automatic delineation of 
PE can be processed and transferred to the treatment 
planning system (TPS). The main goal of this study was to 
evaluate the possibility to transfer and integrate the PE 
information into a radiotherapy plan, and calculate the 
volume of the healthy lung. 
Materials and Methods: We analyzed patients with LC and PE 
treated with RT excluding stereotactic treatments. All 
patients had a diagnostic CT before RT. The PE structure was 
delineated with Myrian© on the diagnostic CT and then 
transferred to the TPS. To permit a good correlation a 
deformable registration was performed between the 
diagnostic CT and the CT dedicated to RT with Velocity AI©. 
We created the healthy lung (HL) structure corresponding to 
the lung excluding the planning treatment volume (PTV) and 
the PE. We compared for each patient the lung-PTV volume 
to the HL volume.  
Results: Nine patients were included in our study, 2 women 
and 7 men. They all had intensity modulated RT. Mean total 
dose was 52.7 Gy (range, 36 – 66). The delay between the 
diagnostic and the planning CT varied between 3 to 111 days. 
The mean PE volume was 322 cm3 (range, 12 – 1394), and the 
mean variation between the lung-PTV volume and HL volume 
was 7.25% (range, 0.33% - 26.22%). Two patients had major 
volume variations respectively 14.8% and 26.22% 
corresponding to a PE volume of 668 and 1394 cm3. 
Conclusions: The transfer of the PE structure previously 
delineated with Myrian© to the TPS is readily feasible. 
Moreover, the difference between the HL and the lung-PTV 
structures can be considerable. It will be of interest to 
analyze the impact of integrating PE information to the 
radiotherapy plan to spare more HL for patients with PE.  
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Purpose/Objective: To evaluate our first cohort of non-small 
cell lung cancer (NSCLC) patients treated with definitive 
radiotherapy using volumetric modulated arc therapy (VMAT). 
Materials and Methods: We analysed 72 consecutive patients 
who received radical non-stereotactic radiotherapy with 
either VMAT (n=33) or 3D-CRT (n=39). Dosimetric comparison 
between the two groups was made. Radiation pneumonitis 
was graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE) v. 4.0. The Chi-square test, 
Fishers exact test or Wilcoxon-Mann-Whitney test were used 
to compare the two groups. 
Results: A significantly higher proportion of VMAT treated 
patients had supraclavicular lymph node involvement (24% vs. 
3%, p=0.009). The risk of developing pneumonitis ≥ gr. 2 was 
12% in the VMAT group vs. 18% in the 3D-CRT group 
(p=0.497). The mean length of the PTV volume was 
significantly longer in the VMAT treated group (11.7 cm vs. 
10.0 cm, p=0.018), but there was no difference in V20Gy 
(24.0 vs. 23.2%, p=0.586), V5Gy (56.4 vs. 52.5%, p=0.228), 
V5Gy to contralateral lung (49.8 vs. 46.8%, p=0.417) or mean 
lung dose (13.7 vs. 14.0 Gy, p=0.782).  
Conclusions: VMAT treatment of NSCLC enabled the inclusion 
of patients with more advanced stages compared to 3D-CRT 
without any significant increase in lung dose.  
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Purpose/Objective: Stage IV NSCLC is characterized by a 
poor prognosis; nevertheless in patients with limited disease 
(1-5 metastases), called oligometastatic disease, has been 
observed a slightly better prognosis. The opportunity for local 
treatment in this stage of disease is not explored yet, but the 
management of oligometastatic disease is controversial. We 
evaluated the impact of a stereotactic body radiotherapy 
(SBRT) delivered in all active sites in the lung in patients with 
oligometastatic/oligorecurrent NSCLC. Response, survival, 
time to progression, sites of progression and toxicity were 
assessed. 
Materials and Methods: Twenty-nine lung metastases (within 
the lung parenchyma) in 22 patients affected by 
oligometastatic NSCLC were treated with SBRT to all active 
sites of disease. Inclusion criteria were controlled primary 
tumor with complete response or stable disease after 
surgery/radiotherapy/combined therapy,≤ 4 synchronous or 
metachronous lung metastases at the time of treatment,and 
no other active sites of distant metastasis. The prescribed 
dose was as follows: 23 Gy/single fraction for multiple 
lesions, 30Gy/single fraction for peripheral or small tumors (< 
30cc), and 45 Gy/3 fractions for centrally located or large 
tumors (≥ 30cc). 
Results: Response to treatment occurred as follow: complete 
response in 21% of lesions, partial response in 69% of 
metastases, stable disease in 10%. Ninety-one (91%) patients 
had complete metabolic response, 9% had a partial metabolic 
response. Median follow-up was 18 months. The 1-year and 2-
years OS was 86% and 49%, respectively. The 1-year and 2-
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years PFS was 79% and 40%, respectively. Median time to 
progression and median OS were 18 months and 24 months, 
respectively. Local control was 93% at 1 year and 64% at 2 
years. Local progression occurred in 4 metastases (14%). 
Overall, acute toxicity occurred in 18% (4/22) of patients; 
two patients experienced grade 2 pneumonitis. Grade 1-2 
late toxicity occurred in 50% of patients. No grade≥3 
toxicities were recorded. 
Conclusions: Local treatment is a feasible and well-tolerated 
treatment for oligometastatic NSCLC patients. Ablative RT 
has a potential role in the local control of the lung 
metastases and in the management of well-selectedstage IV 
NSCLC patients in increasing quality of life and survival. 
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Purpose/Objective: The aim of this study was investigate 
whether the standardized uptake value (SUV-max) of tumor 
from [18F]-fluoro-2-deoxy-glucose positron emission 
tomography (FDG-PET) was associated with outcome in 
patients with non-small-cell lung cancer (NSCLC) treated with 
curative stereotactic body radiotherapy (SBRT). 
Materials and Methods: Between January 2006 and January 
2014, a total of 46 patients with medically inoperable early 
stage NSCLC underwent SBRT. 32/46 (69.57%) and 14/46 
(30.43%) had stage IA and IB, respectively. The treatment 
was administred as 40-50 Gy in 5 fractions; the dose was 
prescribed to the isocenter. Histology was confirmed in 36/46 
(78.26%) patients. All received FDG-PET/computed 
tomography (CT) at the same institution before SBRT, 3-4 
months after the end of SBRT and every 4-6 months 
thereafter. We reviewed the values of the metabolic activity 
of the lung lesion before and after treatment, expressed as 
maximum standardized uptake value (SUV-max) before SBRT 
(SUV-max pre-SBRT), first SUV after SBRT (1st SUV-post-SBRT) 
and the lowest value of SUV in the longitudinal follow-up 
(SUV-nadir). The values were then analyzed with Cox 
proportional hazards regression to assess whether the 
metabolic activity could has a predictive value in treatment 
outcome: local failure (LF), mediastinal failure (MF), 
systemic progression (SP), overall survival (OS) and cancer 
specific survival (CS). 
Results: Median follow-up was 20.5 months (range 4 – 91) for 
whole group. The median SUVmax pre-SBRT was 7.70 
(range,1.4-28.9), median 1st SUV post-SBRT was 3.25 (range 
0.0-9), median SUV-nadir was 1.90 (range 0.0-8). Local 
complete and partial response was observed in 37/46 
(80.43%) and 9/46 (19.57%) patients, respectively. Kaplan-
Meier three-years LF, MF, SP were 18.7%, 5% and 5%, 
respectively. Three-years OS and CS were 67.7% and 82.1%, 
respectively. We have found similar rates of response in 
terms of complete and partial response, even if the SUVmax 
before treatment was higher or lower than the median value 
in our study (7.70). In univariate analysis, SUVmax pre-SBRT, 
1st SUV-post-SBRT and SUV-nadir did not predict for LF, MF, 
SP, OS and CS.  
Conclusions: SBRT was an effective treatment for medically 
inoperable early-stage NSCLC. On the basis of our results PET 
SUV-max pre-SBRT, 1st SUV-post-SBRT and SUV-nadir did not 
predict for LF, MF, SP, OS and CS. 
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Purpose/Objective: A murine breast cancer xenograft model 
was employed to evaluate inter- and intra-variability of 
various parameters derived from dynamic positron emission 
tomography with [18F]fluorodeoxyglucose as tracer (FDG-
PET). 
Materials and Methods: 17 female athymic nude foxn1/nu 
mice with bila-terally implanted triple-negative basal-like 
ductal carcinoma (MAS98.12) breast cancer xenografts 
underwent a dynamic PET scan over an hour after injection 
of ~10 MBq FDG. Inter-animal data were obtained from the 
entire animal cohort, while intra-animal data were obtained 
fro-m four mice which received an additional scan after one 
or two days. Standardised uptake values (SUVmax, SUVmean and 
SUVmedian) were estimated for all tumours and livers at 
different time points. Tumour uptake was analysed with 
Patlak analysis and a full kinetic two-compartment model for 
estimation of pharmacokinetic parameters. The coefficient of 
variation (CV) was calculated for all PET-derived metrics. 
Results: The CV for SUVmean and SUVmedian was typically 10-20% 
for the tumours, depending on the time post injection and 
group (intra vs inter). The CV for SUVmax was mostly higher at 
all time points p.i. The variability in the pharmacokinetic 
parameters ranged from 23 to almost 150%. 
Conclusions: SUVmean and SUVmedian show less variability than 
SUVmax. Still, pharmacokinetic tumour metrics show much 
greater variability than the SUV based metrics. However, it is 
generally not known which of these metrics that best 
represents cancer aggressiveness and their use may still 
depend on the research questions addressed. 
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